RAD51 and non-small cell lung carcinoma: Our result expanded the possibility of olaparib and rapamycin combination further by showing that a low-dose of rapamycin could inhibit Rad51 focus-formation, not only in HR proficient NSCLC cells, but also in BRCA1-mutated TNBC cells by inhibiting the remnant HR mechanism.